Hydroxychloroquine study withdrawn over data concerns
Authors have withdrawn an influential article finding that hydroxychloroquine had no benefit against Covid-19, citing data concerns.
This content was published on
2 minutes
swissinfo.ch/jc
The article, published in the Lancet medical journal on May 22, was by Harvard Medical School, the University of Utah and Switzerland’s University Hospital Zurich. It found that antimalarial drugs hydroxychloroquine and a similar drug chloroquine showed no benefit against Covid-19 and could even increase the risk of heart arrhythmia and death.
But three of the four authors, including Frank Ruschitzka of the University Hospital of Zurich, have now retracted it.
On Thursday, they said that Surgisphere, the company that provided the data, would not transfer the dataset for an independent review and that they “can no longer vouch for the veracity of the primary data sources”. The fourth author of the study, Sapan Desai who is chief executive of Surgisphere, declined to comment on the retraction, according to Reuters.
In a June 5 update to its original press release, Zurich University Hospital department of cardiology said it was “only called in by Harvard Medical School to co-author the paper during the evaluation phase” and “was not involved in the provision of the data by the company Surgisphere or in the evaluation of the data collection”. “Prof. Ruschitzka had no contact with the company,” it adds. “After reservations became known, the authors immediately requested an external audit.”
Controversy
The antimalarial drug has been surrounded by controversy. Claimed by French professor Didier Raoult to be a miracle cure for the new coronavirus, it has also been touted by US President Donald Trump and Brazilian President Jair Bolsonaro. The Lancet article caused the suspension of several studies into its use for Covid-19.
At the height of the pandemic in March, Swiss hospitals all had their own policies with regard to administration of the drug, according to data gathered by Swiss television RTS. In mid-May most of the big hospitals harmonised their practise, deciding to stop using chloroquine to treat Covid-19 except for patients taking part in clinical trials.
The World Health Organization paused hydroxychloroquine trials after The Lancet study was released but said on Wednesday it was ready to resume trials.
Swiss money laundering office registers record number of reports
This content was published on
The Money Laundering Reporting Office Switzerland (MROS) registered a record number of reports of suspicious activity last year.
Two teens accused of planning terror attack released from custody
This content was published on
The Schaffhausen judiciary has released the two teenagers from custody who allegedly planned bomb attacks in Switzerland.
OECD: Sluggish economic activity slowing growth in Switzerland
This content was published on
Sluggish economic activity at the start of the year is weighing on growth in Switzerland, with GDP expected to fall to 1.1% in 2024.
Report finds mistakes which led to Swiss government data breach
This content was published on
Mistakes were made by both the government and internet company Xplain in the case of a criminal cyber-attack on the Bern-based IT business.
Swiss government wants better gender balance in federal administration
This content was published on
New Swiss government personnel management targets say there must be even more female managers in the federal administration.
Swiss national science foundation funded over 5,000 projects in 2023
This content was published on
In 2023, the Swiss National Science Foundation (SNSF) provided a total of CHF961 million worth of funding towards research projects.
Switzerland invites 160 delegations to June Ukraine peace talks
This content was published on
Russia is currently not among the delegations invited to talks aimed at helping bring about peace in the conflict between Moscow and Ukraine.
Survey: air travel most popular way to go on holidays for Swiss
This content was published on
Despite the climate crisis, flying is the most popular mode of transport for private travel – particularly among young, urban and high-income travellers.
Swiss government to use phone data to identify asylum seekers
This content was published on
From April 2025, authorities plan to be able to analyse data from mobile phones, computers and other data carriers to identify asylum seekers.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Balancing hope and science in the search for a coronavirus cure
This content was published on
The debate surrounding the antimalarial drug hydroxychloroquine epitomises companies' balancing act between hope and scientific realities.
Study finds hydroxychloroquine linked to higher death rate in Covid-19 patients
This content was published on
An international research team led by the University Hospital of Zurich and Harvard Medical School finds controversial antimalarial drugs show no benefit against Covid-19.
‘Anti-malaria drug can kill coronavirus’: Novartis chief
This content was published on
Swiss pharmaceutical giant Novartis believes the anti-malaria drug hydroxychloroquine offers one of the best hopes to combat coronavirus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.